NovoCure Ltd (MEX:NVCR)
MXN 275.39 0 (0%) Market Cap: 37.39 Bil Enterprise Value: 31.76 Bil PE Ratio: 0 PB Ratio: 5.23 GF Score: 69/100

Novocure Ltd at Wells Fargo Healthcare Conference Transcript

Sep 07, 2022 / 08:20PM GMT
Release Date Price: MXN1512.48
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst

Hey, good afternoon, everyone. I'm Larry Biegelsen, the medical device analyst at Wells Fargo, and it's my pleasure to host this session with NovoCure. With us, we have Bill Doyle, Executive Chairman; Ashley Cordova, CFO.

In terms of format, it's going to be a fireside chat. If anyone has a question they want to ask, you raise your hand, and we'll call on you. Also in the back, I see Ingrid Goldberg, Vice President of Investor Relations, and Adam Daney. So, thank you so much for being here, Bill and Ashley.

Questions & Answers

Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst

Let's just start with a few big picture questions. The macro environment has been challenging for all medical device companies. You guys have navigated it pretty well. So, I guess the question I have is, how do you see the macro environment playing out over the rest of this year? And can

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot